Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Demand trends and pricing in focus as Delta Airlines gears up for Q4 earnings
Delta Air Lines is preparing to report fourth-quarter earnings, with investors closely watching how the carrier navigated ongoing cost pressures and evolving demand trends. The company's resilient performance in 2025
Lamb Weston (LW) continues to push through a dynamic environment
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) stayed green on Tuesday. The stock has dropped 27% in the past three months. The frozen potato products maker continues to operate
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
